Gland Pharma (GLAND) Share Price Falls 2.45% Today to Rs 3,296.20
- September 10, 2026
- Posted by: Kunal Singla
- Category: News
The Gland Pharma share price is trading at Rs 3,296.20, down 2.45% from the previous close of Rs 3,379.10, as of 17 November 2026 at 10:38 AM IST. The Healthcare company has a market capitalisation of Rs 55,026.17 crore and sits in the Large Cap category on Univest, so the Gland Pharma share price fall is a Large Cap move in today’s stock market updates.
The price move is confirmed in Univest data; a company-specific reason has not been established. The Gland Pharma stock news for this session is therefore the price action itself: a decline of Rs 82.90 per share, an opening level of Rs 3,378.25 and a day range between Rs 3,283.85 and Rs 3,395.00.
On fundamentals, the stock shows a P/E ratio of 45.12, a P/B ratio of 5.22, ROE of 10.56% and ROCE of 14.96%. Investors following the Gland Pharma share price today can monitor how the stock behaves against its previous close, how its valuation compares with the Pharmaceuticals & Drugs benchmark and whether any company announcement follows.
Gland Pharma (GLAND) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 3,296.2 |
| Previous Close | Rs 3,379.1 |
| Today's Move | -Rs 82.90 (-2.45%) |
| Open | Rs 3,378.25 |
| High | Rs 3,395 |
| Low | Rs 3,283.85 |
| Market Capitalisation | Rs 55,026.17 crore |
| Market Cap Category | Large Cap |
The Gland Pharma share price today stands at Rs 3,296.20, a fall of 2.45% or Rs 82.90 per share against the previous close of Rs 3,379.10. The stock opened at Rs 3,378.25, touched a high of Rs 3,395.00 and touched a low of Rs 3,283.85, as of 17 November 2026 at 10:38 AM IST.
The opening level of Rs 3,378.25 was only marginally below the previous close, and the day high of Rs 3,395.00 was Rs 15.90 above that close. From there the Gland Pharma share price moved lower through the morning, and the intraday low of Rs 3,283.85 sits Rs 12.35 below the latest traded level. The full range between the day high and the day low is Rs 111.15.
This is a single-session decline. The consecutive session count is 1, so the cumulative fall of 2.45% since the base price of Rs 3,379.10 is the same as today’s move. With a market capitalisation of Rs 55,026.17 crore and a Large Cap tag, the Gland Pharma stock falling today reflects a larger company moving by a measured margin rather than a small-company swing. The next question is whether the fundamental profile gives any context to the move. Investors can also monitor whether the stock stays inside the day range and how it compares with the previous close of Rs 3,379.10 as the session continues.
Gland Pharma (GLAND) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 55,026.17 crore |
| P/E Ratio | 45.12x |
| P/B Ratio | 5.22x |
| ROE | 10.56% |
| ROCE | 14.96% |
| EPS | Rs 74.9 |
| Book Value Per Share | Rs 647.57 |
| Dividend Yield | 0.59% |
Gland Pharma (GLAND) fundamental metrics show P/E 45.12x, P/B 5.22x, ROE 10.56%, ROCE 14.96%. These ratios show where the company stands today and are not a call to buy or sell.
Gland Pharma has a market capitalisation of Rs 55,026.17 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 45.12x, P/B at 5.22x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 10.56% and ROCE of 14.96%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 74.9, book value per share of Rs 647.57, dividend yield of 0.59%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 30.46x, median ROE of 11.33%, median ROCE of 13.1%. Together they describe the fundamental backdrop without implying a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 45.12x |
| Benchmark Median P/E | 30.46x |
| Benchmark Average P/E | 52.1x |
| Benchmark P/E Range | 2.82x to 1,227.27x |
| Company P/B Ratio | 5.22x |
| Benchmark Median P/B | 2.92x |
| Benchmark Average P/B | 3.28x |
| Company ROE | 10.56% |
| Benchmark Median ROE | 11.33% |
| Benchmark Average ROE | 5.24% |
| Company ROCE | 14.96% |
| Benchmark Median ROCE | 13.1% |
| Benchmark Average ROCE | 12.07% |
| Company Market Capitalisation | Rs 55,026.17 crore |
| Benchmark Median Market Cap | Rs 760.34 crore |
| Benchmark Average Market Cap | Rs 14,899.39 crore |
Gland Pharma (GLAND) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Gland Pharma (GLAND) has a P/E ratio of 45.12x, which is above the benchmark median of 30.46x, a difference of +48.13%. A P/E difference of this kind is a reference point rather than a recommendation.
Gland Pharma (GLAND) has a ROE of 10.56%, which is below the benchmark median of 11.33%, a difference of -6.8%. Gland Pharma (GLAND) has a ROCE of 14.96%, which is above the benchmark median of 13.1%, a difference of +14.2%.
Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,51,290.91 | 40.85 | 5.02 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 3,05,014.11 | 87.71 | 16.39 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,77,333.2 | 83.99 | 9.71 | 26.76 | 19.27 |
| Laurus Labs | LAURUSLABS | 1,30,755.56 | 89.4 | 19.77 | 18.31 | 18.2 |
| Zydus Lifesciences | ZYDUSLIFE | 1,18,802.71 | 28.37 | 4.26 | 19.69 | 21.39 |
Gland Pharma (GLAND) has a P/E ratio of 45.12x compared with the displayed peer median of 83.99x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 10.56% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 14.96% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Gland Pharma (GLAND) has a market capitalisation of Rs 55,026.17 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Gland Pharma
- The Gland Pharma share price is at Rs 3,296.20, down 2.45% from the previous close of Rs 3,379.10.
- The stock moved between Rs 3,283.85 and Rs 3,395.00 after opening at Rs 3,378.25.
- Valuation shows a P/E of 45.12 against a Pharmaceuticals & Drugs median of 30.46.
- ROE of 10.56% and ROCE of 14.96% give a returns picture to read against peers.
- A market capitalisation of Rs 55,026.17 crore places the company in the Large Cap category.
About Gland Pharma
Gland Pharma operates in the Healthcare sector within the Pharmaceuticals & Drugs industry. The company is part of a benchmark group of 200 industry companies, and with a market capitalisation of Rs 55,026.17 crore it ranks well above the industry median of Rs 760.34 crore. Its EPS of Rs 74.90 and book value of Rs 647.57 per share form the base of its per-share profile.
Track Gland Pharma Share Price on Univest
Use Gland Pharma (GLAND) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
Investors can track the live Gland Pharma share price, fundamental ratios such as P/E, P/B, ROE and ROCE, 52-week levels and market insights on Univest. The Univest stock page brings the Gland Pharma share price update, sector context and peer figures together, so the latest Univest figures stay in one place during the trading day.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is the Gland Pharma share price falling today?
Ans. The price move is confirmed in Univest data; a company-specific reason has not been established. The Gland Pharma share price is at Rs 3,296.20, down 2.45% from the previous close of Rs 3,379.10.
What is the current Gland Pharma share price?
Ans. The Gland Pharma share price is trading at Rs 3,296.20 as of 17 November 2026 at 10:38 AM IST. That is Rs 82.90 below the previous close of Rs 3,379.10, a fall of 2.45% in the session.
What is the Gland Pharma market cap?
Ans. Gland Pharma has a market capitalisation of Rs 55,026.17 crore and is classed as a Large Cap on Univest. Market capitalisation shows company size, and it does not indicate the quality of the business.
What are the P/E and P/B ratios of Gland Pharma?
Ans. Gland Pharma has a P/E ratio of 45.12 and a P/B ratio of 5.22. The industry median P/E is 30.46 and the median P/B is 2.92, so both company multiples are above the median.
How does Gland Pharma compare with its industry on returns?
Ans. Gland Pharma has an ROE of 10.56% and an ROCE of 14.96%. The industry median ROE is 11.33 and the median ROCE is 13.10, so ROE is below the median while ROCE is above it.
What are the EPS and book value of Gland Pharma?
Ans. Gland Pharma reports an EPS of Rs 74.90 and a book value of Rs 647.57 per share. EPS shows earnings attributable to each share, while book value shows the accounting net worth behind each share.
What is the dividend yield of Gland Pharma?
Ans. The dividend yield of Gland Pharma is 0.59%. This is a historical and current measure of payout relative to the share price of Rs 3,296.20, and it is not a guarantee of future dividends.
How is Gland Pharma placed against its peers?
Ans. Gland Pharma's P/E of 45.12 is above Sun Pharmaceutical at 40.85 and Zydus Lifesciences at 28.37. Its ROE of 10.56% and ROCE of 14.96% are below all five listed peers in the comparison.
Where can investors track the Gland Pharma share price live?
Ans. Investors can track the live Gland Pharma share price, P/E, P/B, ROE, ROCE, 52-week levels and sector context on Univest. The platform keeps the share price update and peer figures together for easy review.